TB-500 (Thymosin Beta-4 Fragment): Actin-Binding Mechanism, ARISE Ophthalmology Data & Compounding Status

What Is TB-500?

TB-500 is the marketed name for a synthetic short-fragment peptide derived from the active region of Thymosin Beta-4 (Tβ4), the principal intracellular G-actin-sequestering peptide in mammalian cells. Native human Tβ4 is a 43-amino-acid acidic peptide with a reference molecular weight of 4,963.4 g/mol and CAS number 77591-33-4.^[1] The "TB-500" label dates to early veterinary horse-racing literature where a Tβ4-derived fragment was studied as a research tool for soft-tissue repair, and the name has persisted in the research-peptide market.

Two things are worth being precise about up front. First, the marketed compound is not necessarily the full 43-residue Tβ4 protein — it is most often supplied as a synthetic shorter fragment that retains the central actin-binding motif and the N-terminal AcSDKP sequence. Second, full-length Tβ4 used in clinical-grade work (notably the RegeneRx RGN-259 ophthalmic) is a defined recombinant or synthetic 4,963.4 g/mol peptide manufactured under cGMP conditions and is regulatorily distinct from research-grade TB-500 vials.^[3]

For a research reader, the practical takeaway is that TB-500 is best understood as a Tβ4-derived fragment research tool, useful in preclinical actin-biology, cell-migration, and wound-healing models, rather than as a finished clinical product.

Mechanism of Action: Actin Binding, Cell Migration & Angiogenesis

Tβ4 is described in the cell-biology literature as the most abundant member of the β-thymosin family in mammalian cells and the principal sequestering peptide for monomeric G-actin. The peptide binds G-actin in a 1:1 stoichiometric complex, maintains a cytoplasmic G-actin pool, and modulates the equilibrium between G-actin and filamentous F-actin during cytoskeletal remodelling.^[1] Three functional consequences are repeatedly cited:

• Cell migration. By regulating local G-actin availability, Tβ4 modulates lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement — the classical building blocks of wound re-epithelialisation.^[1]
• Angiogenesis. Multiple in-vitro and rodent studies report that Tβ4 promotes endothelial cell migration, tube formation, and collateral vessel growth in ischaemic tissue. The angiogenic phenotype is one of the better-replicated preclinical signals in the Tβ4 literature.^[2]
• Anti-inflammatory and anti-apoptotic signalling. Tβ4 has been shown to reduce inflammatory cytokine output and to lower apoptotic indices in cardiac and corneal injury models, an effect attributed in part to downstream Akt and ILK signalling.^[2]

A distinct mechanistic strand involves the N-terminal tetrapeptide N-acetyl-Ser-Asp-Lys-Pro (AcSDKP). AcSDKP is released enzymatically from the Tβ4 N-terminus and is itself a separately characterised bioactive peptide: it is an endogenous regulator of haematopoietic stem-cell cycling, an anti-fibrotic agent in renal and cardiac models, and a substrate for angiotensin-converting enzyme (ACE), which catalyses its degradation.^[5] When a research reader encounters "TB-500" claims that span actin biology, anti-fibrotic effects, and stem-cell mobilisation, much of that mechanistic breadth is doing the work of two distinct signalling fragments — the central actin-binding motif and the AcSDKP terminal fragment.

What this gives the field is a believable, multi-pathway sketch — actin sequestration plus AcSDKP-mediated anti-fibrotic and haematopoietic signalling — rather than a single-receptor pharmacology.

Preclinical Evidence: Cardiac Repair, Ophthalmology, and Wound Healing

Three preclinical signal sets dominate the modern Tβ4 / TB-500 literature.

1. Cardiac repair after myocardial infarction

Bock-Marquette and colleagues reported in 2004 that systemic Tβ4 administration after experimental myocardial infarction in mice reduced infarct size, improved cardiac function, and promoted survival of cardiomyocytes through Akt-pathway activation and PINCH-ILK-Akt complex signalling.^[2] Follow-up work from the Riley group has explored Tβ4-driven activation of epicardial-derived progenitor cells and collateral vessel growth in mouse models. The cardiac-repair signal is the most cited single mechanistic story in the Tβ4 literature and the backbone of most "Tβ4 heals tissue" narratives.

2. Ophthalmology and corneal wound healing

Tβ4 promotes corneal epithelial cell migration, suppresses inflammatory infiltrates, and accelerates re-epithelialisation in rabbit and rodent corneal injury models. This preclinical signal is the scientific foundation of the RegeneRx RGN-259 ophthalmic programme — a preservative-free Tβ4 0.1% eye drop developed for dry-eye disease and neurotrophic keratitis — discussed in the next section.^[3]

3. Dermal wound healing and tendon / ligament repair

Tβ4 and Tβ4-derived fragments have been studied in full-thickness skin wound, diabetic wound, and pressure-injury rodent models, with reports of accelerated wound closure, reduced inflammation, and increased neovascularisation. A separate strand of mostly preclinical work in rodent tendon and ligament injury models is the most commonly cited basis for athletic-recovery interest in TB-500, although the human late-stage evidence base in musculoskeletal injury remains absent.^[2]

The honest summary across these signal sets is consistent. Tβ4 produces a reproducible preclinical wound-healing and tissue-repair phenotype across multiple organ systems and multiple independent groups. The translational programme that has actually reached late-stage human trials is the ophthalmic one — and even there, the endpoint record is mixed.

RegeneRx RGN-259 ARISE-1 & ARISE-2 — Ophthalmology Phase 3 Status

The clearest human clinical record for Tβ4 is the RegeneRx Biopharmaceuticals ophthalmic programme. RGN-259 is a preservative-free 0.1% Thymosin Beta-4 eye drop developed for dry-eye disease and, in parallel, for neurotrophic keratitis. The programme spans three Phase 3 dry-eye trials — ARISE-1, ARISE-2, and ARISE-3 — conducted under collaboration with regional partners in the U.S. and Asia.^[3]

The published record is mixed. ARISE-1 reported statistically significant improvement in a subset of sign endpoints (notably central corneal fluorescein staining) and certain symptom endpoints, but did not meet all co-primary endpoints. ARISE-2 produced a comparable pattern: some sign and symptom endpoints reached significance in pooled analyses, others did not. ARISE-3 was designed to consolidate the sign/symptom evidence and continued the programme towards a regulatory submission posture. As of April 2026, there is no FDA approval for RGN-259, and Thymosin Beta-4 ophthalmic remains investigational in the U.S. market.^[3]

For a research reader, two implications follow. First, the ophthalmic programme is the most rigorous test of Tβ4 in humans to date and the clearest source of pharmacological detail (dose, vehicle, exposure window, endpoint definitions). Second, the mixed endpoint record undercuts any framing that Tβ4 is a finished, validated human therapy — even in the indication where it has been most extensively studied.

TB-500 vs Full-Length Thymosin Beta-4: The Labelling Question

A labelling clarification belongs near the top of any honest TB-500 review. The peptide widely sold in the research-peptide market under the "TB-500" label is, in most catalogues, a synthetic shorter fragment of Tβ4 rather than the full 43-amino-acid, 4,963.4 g/mol native protein.^[4] The fragment is typically centred on the actin-binding region of Tβ4 and retains the N-terminal AcSDKP sequence in some preparations. It is supplied at the small-molecule scale (typically 2-5 mg lyophilisate) and is comparatively easy to synthesise by solid-phase peptide synthesis.

Full-length Tβ4, by contrast, is the defined 43-residue peptide used in the RegeneRx RGN-259 ophthalmic formulation and in most of the published cardiac and corneal mechanism work. It is the entity to which the CAS reference 77591-33-4 and the 4,963.4 g/mol reference molecular weight apply.^[1]

Two consequences follow for a research reader:

• Literature mapping is not 1:1. Mechanism papers using full-length Tβ4 do not automatically translate to a "TB-500" fragment vial. The actin-binding motif and the AcSDKP fragment are conserved in most marketed TB-500 preparations, but receptor and signalling claims should be read with the actual reagent in mind.
• COA reading matters. When a per-batch Certificate of Analysis is available, the molecular-weight and HPLC retention-time data should be cross-checked against the expected fragment, not against the full 4,963.4 g/mol Tβ4 reference. Researchers comparing TB-500 vials across suppliers will sometimes see meaningful differences in the disclosed fragment composition.

This is research-buyer literacy rather than a critique of the molecule. The fragment is biologically interesting on its own terms. Honest framing simply requires being clear about what is in the vial.

Reconstitution & Storage Protocol

Lyophilized TB-500 is supplied as a stable powder for cold-chain storage. Standard handling for in-vitro research work mirrors the protocols used for other short research peptides:

• Storage of the lyophilisate. 2-8°C protected from light for routine use; -20°C for long-term storage. The UAE summer climate makes documented cold-chain handling from arrival to bench-side important — short ambient excursions during last-mile delivery are the most common stability risk.
• Reconstitution. Bacteriostatic water (0.9% benzyl alcohol as preservative) is the standard reagent. A typical research preparation reconstitutes a 10mg vial in 2-3 mL of bacteriostatic water for laboratory use; the exact volume is a function of the downstream assay concentration and is set by the research protocol. See the Remy bacteriostatic water guide and peptide stability and storage guide for handling depth, and the reconstitution calculator for the per-volume working concentration.
• Post-reconstitution storage. 2-8°C with use inside the research-protocol working window. Reconstituted research-grade Tβ4-fragment solutions are typically used within 2-4 weeks of reconstitution, though stability programmes vary by laboratory.

This page provides no human-use dosing or veterinary instructions and is not a clinical-protocol document.

What the TB-500 Literature Does Not Yet Give You

Cautious reading of the TB-500 / Tβ4 record requires acknowledging four real gaps:

• No registered Phase 2 or Phase 3 musculoskeletal human trial. A clinicaltrials.gov search at the time of writing did not return a Phase 2 or Phase 3 TB-500 or Tβ4 trial registration for tendon, ligament, muscle, or joint injury. The widely cited soft-tissue repair evidence is animal preclinical work, not late-stage human trial evidence.
• No published human pharmacokinetic profile for the marketed fragment. Human PK data for Tβ4 has been generated inside the RegeneRx ophthalmic programme and a handful of small dermatology studies. The systemic PK profile of the synthetic "TB-500" fragment used in the research-peptide market — distribution, clearance, AcSDKP release kinetics in humans — is not characterised in the public literature in a way that supports clinical extrapolation.^[5]
• Dose translation is unsupported. Published animal doses do not map cleanly to a human dose with any rigour, and this article makes no attempt to do so. Anyone offering specific TB-500 protocols for humans is going outside the published data.
• Labelling heterogeneity across suppliers. The marketed "TB-500" fragment is not a single uniformly defined entity. Independent third-party analytical confirmation of the fragment composition is the right baseline for serious laboratory work.

These gaps are not arguments against studying TB-500. They are arguments against overselling it.

TB-500 Research Access in Dubai & UAE

For a UAE-based research catalog operating under MoHAP Circular 17/2022, TB-500 belongs in the category of actin-biology and tissue-repair research peptides — typically supplied as a 10mg lyophilized research vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work. The Remy TB-500 10mg research vial documents the catalog format, pricing tiers, and handling notes; the BPC-157 + TB-500 blend vial is the most commonly co-ordered combination format for researchers running parallel actin-biology and gut-mucosal repair assays.

Material is not framed for human use, not framed for veterinary use, and not framed as a treatment. The wider research catalog comparison sits at /products/, and the COA history sits in the COA library.

For researchers reading this page as a starting point, the most useful adjacent references on this site are the BPC-157 healing peptide review, the KPV tripeptide review, the GHK-Cu copper-peptide review, and — for handling depth — the bacteriostatic water guide and peptide stability and storage guide.

TB-500 vs BPC-157 vs GHK-Cu — Where the Lanes Differ

Researchers commonly ask how TB-500 positions next to other healing-and-repair research peptides. The three most-compared compounds belong to different families and were investigated in different model systems. The table below summarises that, without claiming clinical interchangeability.

None of these molecules is an approved therapeutic in the UAE or US, and none has a peptide-specific late-stage human-trial program of the kind seen with incretin agents. For research framing, the cleanest position is to keep TB-500 in the actin-biology / Tβ4 fragment lane, BPC-157 in the gastric-protein recovery-signalling lane, and GHK-Cu in the skin/copper-remodelling lane. They are not substitutes for each other in a research-design sense.